We are international
Donate
TEXT SIZE   
   back

ASH 2011: Dr. San Miguel - Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)
Jesús F San Miguel, MD PhD
Hospital Clinico Universitario
Salamanca, Spain
12.07.11

Be the first to comment

 related articles